Pioneering drug can halt advance of multiple myeloma for three times as long as standard treatments
Thousands of patients in England with blood cancer will become the first in the world to be offered a pioneering “Trojan horse” drug that sneaks inside cancer cells and wipes them out.
In guidance published on Friday, the National Institute for Health and Care Excellence (Nice) gave the green light to belantamab mafodotin, which can halt the advance of multiple myeloma for three times as long as standard treatments.
The targeted therapy, which is given as an infusion every three weeks with other cancer drugs, is a special type of antibody drug that targets and attaches to cancer cells.
It has been described as a Trojan horse treatment because it works by being taken into a cancer cell and unleashing a high concentration of a lethal molecule to destroy the cell from inside.
